3 Bioeconomy Stocks Investors Should Not Hesitate to Buy
While the words biotech and biopharma are often used interchangeably, they aren't the same thing - not even close, in fact. Source: BioSpace
Korean Firm Draws FDA Warning for GMP Violations, Mislabeling
The FDA warned a Korean manufacturer over significant GMP violations observed during an inspection in March, including its failure to test incoming components. Source: Drug Industry Daily
Insurance Trust Fund Sues Allergan for Anticompetitive Practices
A class of indirect purchasers filed an antitrust suit against Allergan over the transfer of its Restasis patents to the St. Regis Mohawk tribe and other anticompetitive practices that inflated…
Pfizer Settles With Purchasers for $94 Million Over Celebrex Pay-For-Delay Deal
Pfizer reached a $94 million settlement with a class of direct purchasers over claims it used fraudulent patents to keep generic competition off the market for its anti-inflammatory drug Celebrex.…
Trump’s Pick for HHS Tells Senate Drug Prices are Too High
President Trump’s nominee for the next secretary of HHS, former Eli Lilly executive Alex Azar, told the Senate’s health committee Wednesday he agrees prescription drug prices are too high, and…
Why This Overlooked Seattle Drugmaker Could be the Best Biotech Buy Right Now
Omeros is getting a lot of love from investors and analysts these days. Source: BioSpace
Frazier-Backed Mavupharma Scores $20M to Fund STING Program
The Series A funding will be used primarily to advance Mavu's lead drug candidates into the clinic. Source: BioSpace
Alkermes Allegedly Fired 3 Female Employees Who Raised Concerns of Bias
After being criticized earlier this month by U.S. Sen. Kamala Harris, three separate sexual harassment lawsuits have been reported. Source: BioSpace
Boston Scientific Loses $3B on Latest Lotus Valve Delay
A delay in returning its Lotus Edge Aortic Valve System to the market has cost Boston Scientific an estimated $3B loss in market capitalization. Source: BioSpace
Struggling The Medicines Company Deals Its Infectious Disease Biz to Melinta for $270M
The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics. Source: BioSpace
- Go to the previous page
- 1
- …
- 243
- 244
- 245
- 246
- 247
- 248
- 249
- …
- 610
- Go to the next page